|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:administration_setting
|
outpatient setting
|
|
gptkbp:approves
|
gptkb:2017
gptkb:European_Union
gptkb:FDA
gptkb:United_States
|
|
gptkbp:can_be_combined_with
|
gptkb:tremelimumab
|
|
gptkbp:chemical_formula
|
C6424 H9924 N1716 O1980 S44
|
|
gptkbp:clinical_trial
|
gptkb:PACIFIC_trial
Phase III
NCT01693562
NCT02807636
NCT03390574
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:contraindication
|
history of severe hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:excretion
|
primarily through the reticuloendothelial system
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Durvalumab
|
|
gptkbp:indication
|
unresectable stage III non-small cell lung cancer
locally advanced or metastatic urothelial carcinoma
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
monitor for immune-mediated side effects
|
|
gptkbp:knockouts
|
high affinity for PD-L1
|
|
gptkbp:marketed_as
|
gptkb:Imfinzi
|
|
gptkbp:mechanism_of_action
|
immune checkpoint inhibitor
|
|
gptkbp:metabolism
|
not extensively metabolized
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
inhibits PD-L1
|
|
gptkbp:provides_guidance_on
|
included in ESMO guidelines
included in NCCN guidelines
|
|
gptkbp:research_areas
|
gptkb:immunotherapy
oncology
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
every 2 weeks
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
immune-related adverse events
pneumonitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:PD-L1
gptkb:Oncology
|
|
gptkbp:trade
|
gptkb:Imfinzi
|
|
gptkbp:type
|
gptkb:Ig_G1
|
|
gptkbp:used_for
|
treatment of bladder cancer
treatment of non-small cell lung cancer
|
|
gptkbp:weight
|
146 k Da
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|